Trials / Completed
CompletedNCT04887532
A Trial of HR19042 Capsule in Healthy Chinese Subjects
Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR19042 capsule | phase 1 :8mg; phase 2:12mg; phase 3:16mg |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2021-07-27
- Completion
- 2021-07-27
- First posted
- 2021-05-14
- Last updated
- 2021-09-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04887532. Inclusion in this directory is not an endorsement.